TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Up 6.9% – What’s Next?

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)’s share price shot up 6.9% during mid-day trading on Tuesday . The stock traded as high as $1.29 and last traded at $1.09. 1,671 shares traded hands during trading, an increase of 40% from the average session volume of 1,193 shares. The stock had previously closed at $1.02.

TriSalus Life Sciences Trading Down 6.4 %

The company’s 50-day moving average price is $1.15 and its 200 day moving average price is $1.26.

Institutional Investors Weigh In On TriSalus Life Sciences

A hedge fund recently bought a new stake in TriSalus Life Sciences stock. Bluefin Capital Management LLC acquired a new stake in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 115,989 shares of the company’s stock, valued at approximately $189,000.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.